Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...
Zacks Investment Research on MSN
Axsome Therapeutics begins Phase III study on AXS-14 for fibromyalgia
Axsome Therapeutics AXSM announced the initiation of the phase III study called FORWARD with the dosing of the first patient, ...
The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.
FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and ...
The Town of Oliver has once again proclaimed a day in May as Fibromyalgia Awareness Day. During Monday's council meeting, the ...
A study conducted by British researchers found that patients with fibromyalgia (FM) reported improved quality of life following use of medical cannabis pro | Health And Medicine ...
Zenas BioPharma (ZBIO) stock plunges as the company posts late-stage trial data for its lead asset, obexelimab, in ...
The 4th Circuit ruled an ALJ wrongly discounted a claimant’s fibromyalgia testimony and ordered Social Security benefits ...
FibroBiologics is pursuing a development program for FSdC spheroids with the goal of advancing to clinical trials. The data includes comprehensive preclinical pharmacology and efficacy assessments ...
Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and ...
A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...
A university-based study finds a high prevalence of fibromyalgia symptoms, strongly linked to anxiety, stress, and lifestyle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback